CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype

详细信息    查看全文

• 作者：Guopei Luo^a ; ^b ; ^c ; Chen Liu^a ; ^b ; ^c ; Meng Guo^a ; ^b ; ^c ; Jiang Long^a ; ^b ; ^c ; Zuqiang Liu^a ; ^b ; ^c ; Zhiwen Xiao^a ; ^b ; ^c ; Kaizhou Jin^a ; ^b ; ^c ; He Cheng^a ; ^b ; ^c ; Yu Lu^a ; ^b ; ^c ; Quanxing Ni^a ; ^b ; ^c ; Xianjun Yu^a ; ^b ; ^c ; ^{yuxianjun@fudanpci.org}
• 关键词：Pancreatic adenocarcinoma ; Lewis antigen ; Heterogeneity ; CA19-9
• 刊名：Cancer Letters
• 出版年：2017
• 出版时间：28 January 2017
• 年：2017
• 卷：385
• 期：Complete
• 页码：46-50
• 全文大小：743 K
• 卷排序：385

文摘

Long-term survival patients had higher proportion of CA19-9 low-secretion (CA19-9 normal) than that of patients with non long-term survival. The prognosis of CA19-9-Low&Lewis (−) patients was worse than that of CA19-9-Low&Lewis (+). For the CA19-9-Low&Lewis (+) subgroup, chemotherapy plus radiotherapy but not chemotherapy was found to be an independent prognostic factor.